NCT03774446View on ClinicalTrials.gov

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

November 2, 2018

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Cushing Disease

Interventions

DRUG

Seliciclib

Drug: Seliciclib

Trial Locations (1)

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors

lead

Cedars-Sinai Medical Center

OTHER